Company · Healthtech & Bio

Accure Therapeutics

accuretherapeutics.com ↗ ·Barcelona ·Series A

Accure Therapeutics is a Barcelona-based, clinical-stage pharma R&D company developing disease-modifying medicines for central nervous system diseases, with a portfolio of three drug candidates (ACT-01, ACT-02, ACT-03) targeting optic neuritis, multiple sclerosis, Parkinson's disease and epilepsy.

Founded

2020

Founders

News

Rounds

Investors

SectorsBiotech, Pharma R&D, CNS therapeutics, Neurology Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Profile updated 20 Jul 2026

Founders

Laurent Nguyen

Founding CEO & Board Member

Pablo Villoslada

Co-founder, Chief Scientific Officer & Chairman of Scientific Advisory Boards

Global models 5

Cerevel Therapeutics

United States · www.cerevel.com ↗

Clinical-stage CNS-focused biotech built by integrating in-licensed neuroscience assets, later acquired by AbbVie, closely mirroring Accure's disease-modifying CNS drug-development model.

$400MComparable

Alector

United States · www.alector.com ↗

VC-backed clinical-stage biotech developing disease-modifying immuno-neurology therapies for neurodegenerative diseases, same therapeutic-area thesis as Accure.

$355MComparable

Denali Therapeutics

United States · www.denalitherapeutics.com ↗

Heavily VC-funded clinical-stage biotech focused on disease-modifying treatments for neurodegenerative CNS disorders, comparable science-driven CNS platform model.

$340MComparable

Annexon Biosciences

United States · www.annexonbio.com ↗

Clinical-stage biotech targeting complement-mediated neuroinflammatory and neurodegenerative diseases, closely matching Accure's neuroinflammation focus (optic neuritis, MS).

$140MComparable

Vigil Neuroscience

United States · www.vigilneuro.com ↗

VC-backed (Atlas Venture, GV) clinical-stage biotech developing disease-modifying therapies for neurodegenerative diseases, similar early-stage CNS asset-development model to Accure.

$115MComparable

Investors 2

Alta Life Sciences (Aliath Bioventures)

www.aliathbio.com

Investor Spain

Centre for Technological and Industrial Development (CDTI)

www.cdti.es

Investor Spain

Funding rounds 1

Series A · €7.6M

Accure Therapeutics, formed by merging Iproteos and Bionure, launched with a €7.6M Series A led by Alta Life Sciences and backed by CDTI. It…

2020-05-26

News & media 4

Published	Article
2026-03-30	Six promising biotech companies to know in Barcelona ↗ Labiotech.eu
2026-01-06	FDA grants breakthrough therapy designation to Oculis' privosegtor for optic neuritis ↗ Ophthalmology Times
2025-04-07	Accure Therapeutics secures $1.6M from Michael J. Fox Foundation and Luxembourg's national research Fund ↗ Tech.eu
2025-01-10	Accure Therapeutics partner Oculis reached positive phase 2 results for lead neuroprotective therapy ↗ PharmiWeb